Loading…
Maravai LifeSciences Holdings is projected to rise to $4.76 by 2027, a +9% move from its current price of $4.37. MRVI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.23 | $4.37 | $4.52 | +0.03% |
| May 30 | $4.17 | $4.37 | $4.58 | +0.06% |
| May 31 | $4.13 | $4.37 | $4.63 | +0.08% |
| Jun 1 | $4.09 | $4.37 | $4.68 | +0.11% |
| Jun 2 | $4.06 | $4.38 | $4.71 | +0.14% |
| Jun 3 | $4.04 | $4.38 | $4.75 | +0.17% |
| Jun 4 | $4.01 | $4.38 | $4.78 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.01 | $4.38 | $4.78 | +0.20% |
| Week 2 | $3.87 | $4.39 | $4.97 | +0.39% |
| Week 3 | $3.78 | $4.40 | $5.12 | +0.59% |
| Week 4 | $3.69 | $4.40 | $5.25 | +0.79% |
| Week 5 | $3.63 | $4.41 | $5.37 | +0.99% |
| Week 6 | $3.57 | $4.42 | $5.48 | +1.18% |
| Week 7 | $3.51 | $4.43 | $5.59 | +1.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Maravai LifeSciences Holdings, Inc. is a life sciences company that provides products enabling the development of drug therapies, vaccines, gene therapies, and diagnostics across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS, with the TRILINK segment manufacturing and selling products for use in gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics and related nucleic acid tooling and research products.
Founded in 2014 and headquartered in San Diego, California, the company serves biopharmaceutical companies, emerging life sciences research companies, academic research institutions, and diagnostics companies. This breadth supports the key phases of biopharmaceutical development, including nucleic acids for diagnostic and therapeutic applications and antibody-based products to detect impurities during production.
MRVI is currently trading around the $4.40 price level, with a market capitalization of $1.62B and a rank of 2164. These figures place the stock in the smaller-cap segment of the market with a clearly defined public float.
The price outlook, based on the provided forecast, suggests a path of expanding average values over the long horizon. The 2026 average is $4.40 and the 2050 average is $29.79, with progressively higher highs and corresponding ROI projections reaching 577.1% by 2050. The overall trajectory is bullish for the long term, aligned with a history of rising upper and lower bounds across the forecast years.
A major floor 37.2% below — a decisive break under it would weaken the trend.
The nearest floor, 22.4% below — buyers have tended to step in here.
The nearest ceiling, 11.0% above — a clean break opens room to run.
A major ceiling 29.6% above — clearing it would confirm fresh momentum.
Key MRVI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MRVI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.41 | Sell | $4.37 | Sell |
| MA 10 | $4.32 | Buy | $4.33 | Buy |
| MA 20 | $4.19 | Buy | $4.17 | Buy |
| MA 50 | $3.59 | Buy | $3.82 | Buy |
| MA 100 | $3.53 | Buy | $3.60 | Buy |
| MA 200 | $3.31 | Buy | $3.51 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.00 | Neutral |
| Stoch RSI (14) | 17.54 | Buy |
| CCI (20) | 38.59 | Neutral |
| Williams %R (14) | -52.75 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -9.90 | Sell |
| Bollinger %B (20,2) | 0.62 | Neutral |
| Stochastic %K (14) | 47.25 | Neutral |
| TRIX (15) | 1.00 | Buy |
| Awesome (5,34) | 0.53 | Buy |
| Ultimate (7,14,28) | 65.53 | Neutral |
| Momentum (10) | -0.29 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 4.45 | Sell |
| ADX (14) | 25.27 | Buy |
| ATR (14) | 0.12 | Info |
In the near term, the 30-day price range spans from $3.49 to $5.55, illustrating a relatively wide, yet constructive, trading band.
The RSI14 sits at 60, indicating neutral-to-bullish momentum, while the sentiment is labeled as BULLISH overall. The stock trades above the SMA50 of $3.54 and above the SMA200 of $3.29, signaling a constructive trend relative to these moving averages.
Support is identified at $3.06 and resistance at $4.85, framing a near-term technical setup within which price action may oscillate.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.83 | $4.37 | $6.07 | 0% | Neutral | |
| $3.69 | $4.76 | $6.53 | +9% | Neutral | |
| $3.90 | $5.20 | $7.45 | +19% | Neutral | |
| $4.52 | $6.19 | $9.17 | +42% | Bullish | |
| $5.20 | $7.31 | $11.13 | +67% | Bullish | |
| $5.77 | $8.30 | $12.95 | +90% | Bullish | |
| $5.93 | $8.72 | $13.91 | +100% | Bullish | |
| $5.90 | $8.86 | $14.41 | +103% | Bullish | |
| $5.81 | $8.89 | $14.73 | +104% | Bullish | |
| $6.25 | $9.76 | $16.44 | +123% | Bullish | |
| $8.29 | $14.13 | $25.52 | +223% | Bullish | |
| $16.52 | $32.85 | $65.66 | +652% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.83 | $4.37 | $5.18 | +0.00% |
| June 2026 | $3.84 | $4.53 | $5.49 | +3.62% |
| July 2026 | $3.76 | $4.48 | $5.52 | -0.99% |
| August 2026 | $3.81 | $4.58 | $5.71 | +2.18% |
| September 2026 | $3.93 | $4.76 | $5.99 | +3.85% |
| October 2026 | $3.86 | $4.70 | $5.97 | -1.28% |
| November 2026 | $3.74 | $4.58 | $5.87 | -2.45% |
| December 2026 | $3.82 | $4.70 | $6.07 | +2.61% |
Click any year to see its month-by-month MRVI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MRVI is projected to trade between $2.83 and $6.07, averaging $4.37 — a potential gain of 0% from today's $4.37. A consolidation phase looks the most probable path here.
Maravai LifeSciences Holdings's 2027 outlook centres on $4.76, within a $3.69 to $6.53 range. That is up +9% on the projected 2026 average. That marks a +9% change versus current levels. Price action looks broadly range-bound.
By 2028, MRVI could reach as high as $7.45, with a base case around $5.20 and support toward $3.90 — roughly +19% from $4.37. A consolidation phase looks the most probable path here.
Expect MRVI to range from $4.52 to $9.17 through 2029. The $6.19 average target implies a +42% move from current prices. That is up +19% on the projected 2028 average. Momentum favours further upside here.
The MRVI price prediction for 2030 points to an average of $7.31 (low $5.20, high $11.13) — a potential gain of +67% on today's $4.37. Buyers look set to stay in control over this stretch.
In 2031, MRVI is projected to trade between $5.77 and $12.95, averaging $8.30 — a potential gain of +90% from today's $4.37. That is up +14% on the projected 2030 average. Momentum favours further upside here.
Maravai LifeSciences Holdings's 2032 outlook centres on $8.72, within a $5.93 to $13.91 range. That is up +5% on the projected 2031 average. That marks a +100% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MRVI could reach as high as $14.41, with a base case around $8.86 and support toward $5.90 — roughly +103% from $4.37. Momentum favours further upside here.
Expect MRVI to range from $5.81 to $14.73 through 2034. The $8.89 average target implies a +104% move from current prices. That is up 0% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MRVI price prediction for 2035 points to an average of $9.76 (low $6.25, high $16.44) — a potential gain of +123% on today's $4.37. Momentum favours further upside here.
In 2040, MRVI is projected to trade between $8.29 and $25.52, averaging $14.13 — a potential gain of +223% from today's $4.37. That is up +45% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Maravai LifeSciences Holdings's 2050 outlook centres on $32.85, within a $16.52 to $65.66 range. That is up +133% on the projected 2040 average. That marks a +652% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MRVI today (≈ 228.832952 MRVI) could be worth
$7,516.16
+$6,516.16 (+652%) by 2050 · US Dollar
Based on the average projected MRVI price of $32.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MRVIwould be worth at today's price.
$1,000 invested in MRVI on May 27, 2025 (≈ 448.430489 MRVI) would be worth
$1,959.64
+$959.64 (+96.0%) today · 1.96× · US Dollar
Based on a MRVI entry price of $2.23 vs. today's $4.37.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.43 | $986.46 | -1.4% |
| 1 month ago | $3.68 | $1,187.5 | +18.7% |
| 3 months ago | $3.56 | $1,227.53 | +22.8% |
| 6 months ago | $3.62 | $1,207.18 | +20.7% |
| 1 year ago | $2.23 | $1,959.64 | +96.0% |
| All time (5.0y) ago | $38.02 | $114.94 | -88.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MRVI forecast.
Our base-case forecast reaches $8.70 around 2032.
Implied market cap at $8.70: $1.28B
The multi-year forecast shows a clear upside path. In 2026 the average is $4.40 with a min of $2.83 and a max of $6.15, and the ROI is 0 with a NEUTRAL sentiment. By 2027 the average rises to $4.66 (min $3.59, max $6.47) as ROI advances to 5.9 with NEUTRAL sentiment, and by 2028 the average is $5.03 (min $3.73, max $7.29) with an ROI of 14.2 and NEUTRAL sentiment.
From 2029 onward, the forecast turns more bullish: 2029 averages $5.97 (min $4.30, max $8.97) with ROI 35.7 and BULLISH sentiment; 2030 averages $6.95 (min $4.87, max $10.74) with ROI 57.9 and BULLISH sentiment. The progression continues with 2031 at $7.94 (min $5.42, max $12.59, ROI 80.4) and 2032 at $8.34 (min $5.57, max $13.53, ROI 89.5), both BULLISH.
Looking further ahead, 2033 and 2034 show averages of $8.24 (min $5.38, max $13.64) and $8.24 (min $5.26, max $13.91) with ROI 87.2 in both years, followed by 2035 at $9.05 (min $5.66, max $15.54) with ROI 105.6. By 2040 the average reaches $12.85 (min $7.31, max $23.74) with ROI 192, and by 2050 the average is $29.79 (min $14.28, max $61.16) with ROI 577.1. Throughout these long-range years, sentiment remains BULLISH, reflecting a sustained upside trajectory, albeit with inherent uncertainty and volatility.
Tap a question to reveal the answer.
The 2030 forecast lists an average price of $6.95 with a min of $4.87 and a max of $10.74, and a forecasted ROI of 57.9% with a BULLISH sentiment.
The long-term view shows increasing averages and a rising ROI, culminating in a 2050 average of $29.79 and an ROI of 577.1% with a BULLISH sentiment. However, these are estimates, not guarantees, and near-term values can vary.
Yes. The 2030 forecast includes a max of $10.74, indicating the possibility of hitting around $10 within that year, though the average is $6.95 and the outcome is not guaranteed.
The current price is $4.40.
In the long term, the forecast shows significant upside: 2040 average $12.85 and 2050 average $29.79, with ROIs of 192 and 577.1 respectively, both labeled BULLISH despite forecast uncertainties and market volatility.
Maravai LifeSciences Holdings Community Discussion
0Share your Maravai LifeSciences Holdings price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.